Clinical trials: Post-ERCP Pancreatitis
Post-ERCP Acute Pancreatitis
ESGE-Quality Improvement in Endoscopy: ERCP
The primary aim of the present study is to compare the incidence of post-ERCP pancreatitis (PEP) before and after the implementation of the QIC-guideline in 2017: "Performance measures for ERCP and endoscopic ultrasound: a…
- Trial name
- QIC_ERCP (NCT06727851)
- Where
- Germany
- Volunteers
- 1,254 people
- Sponsor
- Universität Münster
Cholangitis, Post-ERCP Acute Pancreatitis
Optimal Placement Duration of Pancreatic Duct Stent
A randomized controlled trial to determine the optimal placement duration of pancreatic duct stents (PDS) inserted during ERCP: 2 vs 4 weeks
- Conditions
- Cholangitis, Post-ERCP Acute Pancreatitis, Stent Dislodgement
- Trial name
- NCT04691674
- Testing
- Endoscopy
- Where
- South Korea
- Volunteers
- 122 people
- Sponsor
- DongGuk University
Post-ERCP Acute Pancreatitis, NSAIDs
Prevention of Post-ERCP Pancreatitis by Indomethacin vs Diclofenac
Post-ERCP pancreatitis (PEP) is the most common complication after ERCP, which was associated with occasional mortality, prolonged hospital days and increased health costs.
- Conditions
- Post-ERCP Acute Pancreatitis, NSAIDs, Indomethacin, Diclofenac
- Trial name
- NCT05947461
- Testing
- 100mg diclofenac, 100mg indomethacin
- Where
- 11 sites in China
- Volunteers
- 1,204 people
- Sponsor
- Air Force Military Medical University, China
Post-ERCP Pancreatitis
Stent vs. Indomethacin for Preventing Post-ERCP Pancreatitis
Background: Pancreatitis is the most frequent complication of endoscopic retrograde cholangiopancreatography (ERCP), accounting for substantial morbidity, occasional mortality, and increased health care expenditures.
- Trial name
- SVI (NCT02476279)
- Testing
- Indomethacin 100 mg rectally immediately after ERCP, NO prophylactic pancreatic stent placement, Indomethacin 100 mg rectally immediately after ERCP AND prophylactic pancreatic stent placement
- Where
- 20 sites in United States, Canada
- Volunteers
- 1,950 people
- Sponsor
- Medical University of South Carolina
Post-ERCP Acute Pancreatitis
Statins and Post-ERCP Acute Pancreatitis (Stark Project)
Post-endoscopic retrograde cholangiopancrepatography (ERCP) acute pancreatitis (PEAP) is a frequent complication of this endoscopic procedure.
- Trial name
- Stark (NCT06367322)
- Testing
- Statin
- Where
- 2 sites in Spain
- Volunteers
- 1,016 people
- Sponsor
- Hospital General Universitario de Alicante
Post-ERCP Acute Pancreatitis
Prediction of PEP Based on the Appearance of the Major Duodenal Papilla
This observational, prospective study aims at evaluating how the occurrence of post-Endoscopic Retrograde CholangioPancreatography (ERCP) acute pancreatitis (PEP) could be influenced by difficult biliary cannulation that might be…
- Trial name
- PredERCP (NCT05800626)
- Testing
- Endoscopic Retrograde Cholangio-Pancreatography (ERCP)
- Where
- 2 sites in Italy
- Volunteers
- 1,740 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Post-ERCP Acute Pancreatitis, Pancreatic Stent
Establishing a Sonographic Based Algorithm to Verify Pancreatic Stent Position Placed to Prevent Post-ERCP Pancreatitis Before Endoscopic Removal
The present study is a prospective, single-center study. A total of 88 patients, who had placed a pancreatic stent for preventing post-ERCP pancreatitis, will be included in the study.
- Conditions
- Post-ERCP Acute Pancreatitis, Pancreatic Stent, Ultrasound, X-rays
- Trial name
- NCT04546867
- Testing
- Sonographic based visualization of a pancreatic stent
- Where
- Germany
- Volunteers
- 88 people
- Sponsor
- Johann Wolfgang Goethe University Hospital
Post-ERCP Acute Pancreatitis
PAN-PROMISE to Detect Post-ERCP Pancreatitis Symptoms
The aim of this study is to use a validated patient-reported outcome measure to evaluate how many patients have symptoms of pancreatitis after ERCP and how it correlates with their quality of life and productivity.
- Trial name
- PAN-PROMISE (NCT05310409)
- Where
- 2 sites in United States
- Volunteers
- 700 people
- Sponsor
- University of Pennsylvania
Post-ERCP Acute Pancreatitis
Randomized Controlled Trial of Rectal Indomethacin Versus Combined Pancreatic Stent Placement and Rectal Indomethacin for Preventing Post-ERCP Pancreatitis
The goal of this clinical trial is to compare rectal indomethacin alone versus combined pancreatic duct stenting and rectal indomethacin in prevention of post ERCP pancreatitis.
- Trial name
- NCT05857514
- Testing
- Rectal Indomethacin, Prophylactic Pancreatic duct stenting
- Where
- 2 sites in India
- Volunteers
- 384 people
- Sponsor
- Moti Lal Nehru Medical College
Post-ERCP Acute Pancreatitis
Urine Trypsinogen 2 Dipstick for the Early Detection of Post-ERCP Pancreatitis
Post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis (PEP) is the most common, serious complication of ERCP. More than 500,000 ERCP procedures are performed from which 25,000 cases of PEP occur in the U.S.A.
- Trial name
- NCT03098082
- Testing
- Actim Pancreatitis
- Where
- United States
- Volunteers
- 394 people
- Sponsor
- Indiana University
Post-ERCP Pancreatitis
Effects of High FIO2 on Post-ERCP Pancreatitis.
Post-ERCP pancreatitis is one of the most common complications accounting for substantial morbidity and mortality. The incidence of post-ERCP pancreatitis (PEP) has been studied in several large clinical trials and ranges from…
- Trial name
- NCT04876768
- Testing
- Use of different concentrations of oxygen during ERCP
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Syed Z. Ali, MD
Post-ERCP Pancreatitis
Refeeding in Post-ERCP Pancreatitis
Endoscopic retrograde cholangio-pancreatography (ERCP) is the most commonly used technique for diagnosis and treatment in the treatment of bile duct diseases including bile duct cholelithiasis and malignant/benign biliary…
- Trial name
- NCT04750044
- Testing
- early refeeding, delayed refeeding
- Where
- 9 sites in South Korea
- Volunteers
- 80 people
- Sponsor
- Yonsei University
Post-ERCP Acute Pancreatitis
ERCP-induced and Non-ERCP Induced Acute Pancreatitis: Two Distinct Clinical and Immunological Entities?
Post endoscopic pancreatitis (PEP) has different initial immunologic response to primary injury compared to acute pancreatitis of other etiology (non-PEP AP).
- Trial name
- NCT02602574
- Testing
- heparinized peripheral venous blood and urine sample.
- Where
- Croatia
- Volunteers
- 66 people
- Sponsor
- University Hospital Rijeka
Post-ERCP Pancreatitis, Pancreatitis, Acute Necrotizing
The Efficacy of Pancreatic Duct Stenting With Rectal Indomethacin in Preventing Post-ERCP Pancreatitis
With the development of endoscopic technology, ERCP has been widely used in the diagnosis and treatment of pancreatobiliary diseases, and has become the first treatment for most of the biliary and pancreatic diseases.
- Trial name
- NCT03643900
- Testing
- pancreatic duct stenting, rectal indomethacin
- Where
- China
- Volunteers
- 618 people
- Sponsor
- First People's Hospital of Hangzhou
Post-ERCP Acute Pancreatitis
Evaluation of Post-ERCP Pain as a Predictor for Post-ERCP Pancreatitis
Pancreatitis is the most common complication after ERCP, although its frequency varies significantly depending on the study from < 2% up to 40%.
- Trial name
- PEP-PREPARE (NCT04770857)
- Testing
- Visual analogue scale
- Where
- Switzerland
- Volunteers
- 1,000 people
- Sponsor
- Nicola Frei
Post-ERCP Acute Pancreatitis
Hemin to Prevent Post-ERCP (Endoscopic Retrograde Cholangiopancreatography) Acute Pancreatitis
ERCP (endoscopic retrograde cholangiopancreatography) has been largely demonstrated to be effective in multiple bilio-pancreatic indications.
- Trial name
- NCT01855841
- Testing
- Hemin
- Where
- 6 sites in Belgium, Taiwan
- Volunteers
- 284 people
- Sponsor
- Erasme University Hospital
Post ERCP Pancreatitis
Intramuscular Diclofenac in the Prevention of Post-ERCP Pancreatitis
Pancreatitis is one of the major complications of ERCP. It has been shown that NSAIDs are potent inhibitors of phospholipase A2, activity which is increased in pancreatitis.
- Trial name
- NCT01717599
- Testing
- Diclofenac, normal saline
- Where
- South Korea
- Volunteers
- 343 people
- Sponsor
- Yonsei University
Post-ERCP Pancreatitis
Magnesium Sulfate in the Prevention of Post-ERCP Pancreatitis.
MagPEP is a multi-centre, randomized, phase III, double blind, placebo controlled, parallel group trial. It evaluates magnesium sulfate for the prevention of post-ERCP pancreatitis.
- Trial name
- MagPEP (NCT03749590)
- Testing
- Magnesium Sulfate
- Where
- Germany
- Volunteers
- 327 people
- Sponsor
- University Medicine Greifswald
Post-ERCP Acute Pancreatitis
Rectal Indomethacin Versus Rectal Indomethacin and Sublingual Nitrate for PEP Prevention
Patients undergoing endoscopic retrograde cholangiopancreatography (ERCP) are at risk for post-ERCP pancreatitis (PEP), which is associated with adverse outcomes.
- Trial name
- NCT04425993
- Testing
- Isosorbide Dinitrate 5 MG, Indomethacin 100 MG
- Where
- 4 sites in China
- Volunteers
- 2,700 people
- Sponsor
- Air Force Military Medical University, China
Post-ERCP Acute Pancreatitis
Study of Effectiveness of Thoracic Epidural Analgesia for the Prevention of Acute Pancreatitis After ERCP Procedures
For 40 years, the post-ERCP (endoscopic retrograde cholangiopancreatography) pancreatitis has been the most frequent adverse effect of endoscopic transpapillary interventions.
- Trial name
- NCT01964066
- Testing
- ERCP, Thoracic epidural analgesia, Premedication
- Where
- Russia
- Volunteers
- 491 people
- Sponsor
- Volgograd State Medical University